Welcome to our dedicated page for Beyondspring news (Ticker: BYSI), a resource for investors and traders seeking the latest updates and insights on Beyondspring stock.
BeyondSpring Inc. (NASDAQ: BYSI) generates a steady flow of news centered on the clinical and regulatory progress of its lead asset, Plinabulin, and on its corporate and financing activities. As a clinical-stage biopharmaceutical company focused on cancer, BeyondSpring’s updates often highlight new data from phase 2 and phase 3 trials in non-small cell lung cancer (NSCLC) and other tumor types, as well as mechanistic findings related to Plinabulin’s dendritic cell maturation and immune-modulating properties.
News releases frequently cover results from major oncology conferences and journals. Examples include presentations at the American Society of Clinical Oncology (ASCO), the IASLC/ASCO North America Conference on Lung Cancer (NACLC), the Society for Immunotherapy of Cancer (SITC), Immuno-Oncology 360°, and ESMO Asia, along with peer-reviewed publications in outlets such as Lancet Respiratory Medicine and Med (Cell Press). These communications describe outcomes from the DUBLIN‑3 phase 3 trial, the 303 and 302 phase 2 studies, and basket trials combining Plinabulin with checkpoint inhibitors, chemotherapy, and radiation.
Investors following BYSI news can also expect regular financial updates, including quarterly results, cash position, and operating expense trends, as well as 10‑K filing announcements. Corporate news items address equity financings, such as registered offerings of ordinary shares, and strategic transactions involving BeyondSpring’s equity stake in SEED Therapeutics, a targeted protein degradation company co-founded by BeyondSpring.
For market participants tracking oncology pipelines, the BYSI news stream provides insight into Plinabulin’s clinical performance, safety profile, biomarker research, and planned registrational strategies, including the company’s intention to advance confirmatory trials like DUBLIN‑4. Bookmarking the news page allows readers to monitor how new data, conference presentations, and SEC-referenced announcements may influence the development trajectory of Plinabulin and BeyondSpring’s broader strategy.
BeyondSpring (NASDAQ: BYSI) announced positive topline data from its PROTECTIVE-2 Phase 3 study, demonstrating that plinabulin combined with pegfilgrastim significantly prevents Grade 4 neutropenia in chemotherapy patients (31.5% vs. 13.6%, p=0.0015). The combination also achieved significant secondary endpoints, impacting duration of severe neutropenia and absolute neutrophil count. With Breakthrough Therapy designations from the U.S. FDA and China NMPA, BeyondSpring is preparing for NDA submission in Q1 2021. The study included 221 patients and provides promising insights for addressing chemotherapy-induced neutropenia in up to 440,000 U.S. patients annually.
BeyondSpring, a biopharmaceutical company trading on NASDAQ under the symbol BYSI, will present a corporate overview at the Jefferies London Healthcare Conference on November 17, 2020, at 2:55 pm Eastern Time. The event will highlight the company's innovative immuno-oncology therapies aimed at patients with high unmet medical needs. Plinabulin, their lead immune asset, is undergoing Phase 3 trials for chemotherapy-induced neutropenia and non-small cell lung cancer. The presentation can be accessed via a live webcast and archived on their official website.
Seed Therapeutics, a subsidiary of BeyondSpring, announced a collaboration with Eli Lilly to develop targeted protein degradation (TPD) therapies. The agreement includes a $10 million upfront payment and a $10 million equity investment from Lilly. Seed Therapeutics could receive up to $780 million in milestone payments and royalties from resulting products. The company aims to address previously undruggable proteins linked to diseases like cancer and Alzheimer's, utilizing its proprietary 'molecular glue' technology to create new therapeutic options.
Seed Therapeutics, a subsidiary of BeyondSpring (NASDAQ: BYSI), has appointed Edward Dongheng Liu as its new Chief Financial Officer. Liu, who has been BeyondSpring's CFO since 2018, will leverage his extensive experience in investment banking and corporate development to enhance the financial strategies of Seed Therapeutics. The company focuses on a molecular glue platform for targeted protein degradation, aiming to address diseases previously deemed undruggable. This appointment is expected to bolster Seed's position in the innovative drug discovery landscape.
BeyondSpring Inc. (NASDAQ: BYSI) announced the formation of a Partnership Advisory Committee to enhance business development efforts for its lead asset, Plinabulin. This committee comprises senior executives from major pharmaceutical companies, including Mukul Agarwal from Forty Seven and Dr. Daniel Zabrowski from Roche. The committee's goal is to facilitate successful partnerships as BeyondSpring approaches the filing of its New Drug Application (NDA) for Plinabulin, which recently received Breakthrough Therapy Designation from the FDA and NMPA for preventing chemotherapy-induced neutropenia.
BeyondSpring (NASDAQ: BYSI) announced promising new clinical data for its lead candidate, Plinabulin, effective in preventing chemotherapy-induced neutropenia (CIN) during the COVID-19 pandemic. Presented at the ESMO Virtual Congress, Plinabulin showed comparable efficacy to Pegfilgrastim (Peg) in preventing severe neutropenia, while offering additional benefits such as reduced bone pain and improved platelet counts. The company has initiated an Expanded Access Program to facilitate access to Plinabulin for clinicians and patients in need during this crisis.
BeyondSpring (NASDAQ: BYSI) recently announced the appointment of Elizabeth Czerepak as Chief Financial Officer, effective immediately. This change comes as the company has received two Breakthrough Therapy Designations for Plinabulin in treating chemotherapy-induced neutropenia in the U.S. and China. BeyondSpring aims to enhance patient care and capitalize on the growing CIN market, valued at over $7 billion annually. Simultaneously, Seed Therapeutics appointed Edward Liu as CFO, strengthening leadership as the firm transitions to commercialization.
BeyondSpring (NASDAQ: BYSI) announced a corporate overview presentation scheduled for September 14, 2020, at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference. The live webcast will be accessible on BeyondSpring's website under the Investors section. The company focuses on developing immuno-oncology therapies to address high unmet medical needs. Its lead asset, Plinabulin, is in Phase 3 trials for chemotherapy-induced neutropenia and non-small cell lung cancer treatment. BeyondSpring also boasts a diverse pipeline, including pre-clinical assets and a novel drug discovery platform.
BeyondSpring has announced that Plinabulin received Breakthrough Therapy Designation from both the FDA and China's CDE for the prevention of Chemotherapy-Induced Neutropenia (CIN). This designation is based on promising results from the PROTECTIVE-2 Phase 3 study, indicating significant advancements in CIN treatment, where Plinabulin showed a substantial improvement in preventing severe neutropenia compared to G-CSF agents. The company plans to submit an NDA to the FDA by the end of 2020, following the full data report from the study.
BeyondSpring reported positive interim results from the PROTECTIVE-2 Phase 3 trial demonstrating that Plinabulin combined with Neulasta significantly reduces the rate of Grade 4 neutropenia. The trial's enrollment of 221 patients has been completed, and results will be finalized in Q4 2020. The company expects to submit an NDA to the FDA for Plinabulin's CIN indication by the end of 2020. Financially, R&D expenses rose to $11 million for Q2 2020, resulting in a net loss of $12.8 million.